Stock Market & Financial Investment News

News Breaks August 30, 2012 13:36 EDT STJ St. Jude Medical sees pre-tax charges of $50M-$80M In connection with this realignment, the Company expects to incur total pre-tax charges of approximately $50M-$80M. This estimate is comprised of $30M-$40M of employee termination costs, including severance and other benefits, and $20M-$40M in accelerated depreciation, asset impairments and other costs. The Company estimates that approximately $35M-$45M of the charges will result in future cash expenditures. The majority of the restructuring activities and related charges will be initiated in the third quarter of 2012 and are expected to be substantially complete within the next twelve months. News For STJ From The Last 14 Days Check below for free stories on STJ the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 11, 2013 16:08 EDT STJ FDA approves St. Jude Medical devices with new safety features St. Jude Medical announced FDA approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery. June 10, 2013 12:22 EDT STJ St. Jude's Durata backed by doctor who found Riata defect, Bloomberg says Subscribe for More Information June 7, 2013 11:05 EDT STJ St. Jude invests $40M in Spinal Modulation, gets exclusive option to acquire St. Jude Medical and privately-held Spinal Modulation announced that they have entered into a series of agreements under which St. Jude Medical made a $40M equity investment in Spinal Modulation, a company that has developed an innovative neuromodulation therapy that provides a new pain management option for patients with chronic, intractable pain. The agreement provides St. Jude Medical with an exclusive option to distribute the Axium Neurostimulator System, developed and manufactured by Spinal Modulation, in international markets where it is approved for sale. Additionally, St. Jude Medical will have the exclusive option to acquire the company for up to $300M plus certain revenue-based milestones following U.S. commercialization. Sign up for a free trial to see the rest of the stories you've been missing.